|
 |
|
 |
|
 |
 |
|||
Portfolio Companies
Abingworth Bioventures V Co-Invest Growth Equity Fund
- Amarin
- (Dublin, Ireland, and Connecticut, CT) is a publicly traded biopharmaceutical company focusing on cardiovascular disease. The company’s lead product is a prescription grade omega-3 fatty acid in Phase III trials for the treatment of hypertriglyceridaema and mixed dyslipidaemia. Amarin is a VIPE (Venture Investment in Public Equity) and is listed on the Nasdaq stock exchange. (10/09)
- Epigenomics
- (Berlin, Germany) is developing oncology diagnostics based on DNA methylation patterns. The company has launched two diagnostics in Europe: a blood test for the early detection of colorectal cancer and a bronchial lavage test for the detection of lung cancer. Methylation patterns are changed in certain disease states, potentially giving rise to diagnostic and therapeutic opportunities. Epigenomics is a VIPE (Venture Investment in Public Equity) and is listed on the Frankfurt stock exchange. (04/10)
- Secure EDI
- (North Carolina, US) is a healthcare transactions integrator, creating electronic interfaces between medical and dental providers and payors. The company’s suite of Web-based services increases efficiency and helps to reduce costs through real-time adjudication of claims, electronic funds transfers, on-line reconciliation and data mining and informatics. (04/10)
(Dates in brackets indicate when the first investment was made.)